Tikun-Olam Cannbit reported the first and exclusive partnership of its kind with Wavelength, an Israeli company that develops, manufactures, and exports active pharmaceutical ingredients (APIs) for the pharmaceutical industry, to over 280 pharmaceutical companies in 50 different countries. Wavelength is a portfolio company of SK Capital Partners, a US-based investment firm with over $5 billion in assets under management, including 125 plants in 28 countries. Under the agreement, Tikun Olam-Cannbit and Wavelength will jointly develop, manufacture and market APIs, or in other words, active cannabis-based raw materials for the pharmaceutical industry.